Uncategorized
Opinion: Hosting the ‘intellectual wrestling match’ between MAHA, public health
The deep distrust between public health and the Make America Healthy Again movement may seem impossible to heal. But the podcast “Why Should I Trust You?” is trying to do just that by facilitating conversation between people who often view each others as enemies.
Brinda Adhikari and Tom W. Johnson launched “Why Should I Trust You?” in 2025. Since then, they’ve hosted big names from MAHA, the Trump administration, the anti-vaccine movement, and traditional health. They also bring on everyday Americans trying to keep their families healthy while navigating a confusing information ecosystem. “Everyone, when they come on the show, no matter what their quote unquote, expertise, they’re all equals. Everyone gets time to speak,” Adhikari said.
The deep distrust between public health and the Make America Healthy Again movement may seem impossible to heal. But the podcast “Why Should I Trust You?” is trying to do just that by facilitating conversation between people who often view each others as enemies.
Brinda Adhikari and Tom W. Johnson launched “Why Should I Trust You?” in 2025. Since then, they’ve hosted big names from MAHA, the Trump administration, the anti-vaccine movement, and traditional health. They also bring on everyday Americans trying to keep their families healthy while navigating a confusing information ecosystem. “Everyone, when they come on the show, no matter what their quote unquote, expertise, they’re all equals. Everyone gets time to speak,” Adhikari said.
Uncategorized
Amgen shores up Tavneos’ FDA defense with Duke data analysis
Amgen shores up Tavneos’ FDA defense with Duke data analysis
After the FDA flagged patient deaths linked to Amgen’s rare disease drug Tavneos and called for its voluntary removal, the pharma recruited an independent data analysis from Duke researchers to help build the case for the drug’s continued market approval. Read More
Uncategorized
Chile offers new data on food warning label efficacy
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
So much news today that I didn’t have space to write an item about hot tubs as a breeding ground for Legionnaires’ disease. Here’s the CDC report, if you’re curious.
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
So much news today that I didn’t have space to write an item about hot tubs as a breeding ground for Legionnaires’ disease. Here’s the CDC report, if you’re curious.
Uncategorized
Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win
The RNA-based medicine is one of a handful of antibody-oligonucleotide conjugates that Novartis acquired last October when it took over neuromuscular-focused Avidity Biosciences.
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Uncategorized9 years agoAccording to Dior Couture, this taboo fashion accessory is back
-
Endpoints News3 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized9 years agoPhillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years agoUber and Lyft are finally available in all of New York State
-
Contributors9 years agoThe final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years agoSteph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years agoThe old and New Edition cast comes together to perform